IBCN 2018: Inhibitors of Metabolic Processes in Bladder Cancer Cells
Rotterdam, The Netherlands (UroToday.com) Piyush Agarwal profiled 14 bladder cancer cell lines for their relative dependence on glycolysis or oxidative phosphorylation to establish their metabolic phenotype and targeted key metabolic enzymes, lactate dehydrogenase (LDH) and nicotinamide phosphoribosyl transferase (NAMPT), with specific novel inhibitors in pre-clinical bladder cancer models.
IBCN 2018: Multispectral Imaging Enables Multiparametric Cystoscopy and Transurethral Resection of Bladder Cancer
Rotterdam, The Netherlands (UroToday.com) Christian Bolenz presented his research using a real-time multispectral imaging (rMSI) device in bladder cancer patients. White light (WL) cystoscopy and transurethral resection (TUR) are the gold standard initial procedures for the detection and treatment of bladder cancer (BC). To overcome limited sensitivity of existing imaging techniques (e.g. PDD) they developed a real-time multispectral imaging (rMSI) device, enabling simultaneous imaging of reflectance and fluorescence modalities in up to 6 spectral bands.
IBCN 2018: Inhibition of a G9a/EZH2 Network Triggers an Immune-Mediated Bladder Cancer Regression
Rotterdam, The Netherlands (UroToday.com) Jesús Paramio presented his prior work regarding the roles of G9a (EHMT2), a H3K9 methyltransferase, in human bladder cancer (BC), and explored whether a novel, reversible, potent and dual inhibitor of G9a/DNMT methyltransferase activity (CM-272) could be of benefit for the management of advanced BC.
IBCN 2018: Bladder Cancer and Therapy from an Immunologist's Perspective
Rotterdam, The Netherlands (UroToday.com) The bladder contains many immune populations which contribute to benign and malignant bladder conditions. Immunologists use models to understand the immune system and bladder cancer. An example is the use of a BBN mouse model to give heterogeneous tumors.
IBCN 2018: Lentiviral Interferon: A Novel Method for Gene Therapy in Bladder Cancer
Rotterdam, The Netherlands (UroToday.com) Colin Dinney presented data regarding gene therapy for bladder cancer (BLCA). He reported that intravesical adenoviral interferon-alpha (Ad-IFNα) produced a complete response in 35% of patients with BCG-unresponsive BLCA enrolled in a Phase II trial. Lentivirus (LV) is another potential vector for intravesical delivery of IFNα. Unlike the adenovirus, LV can infect non-dividing cells and integrate into the host’s genome, making it one of the most efficient gene delivery vectors. The objective of this study was to investigate lentiviral interferon-alpha (LV-IFNα) BLCA gene therapy in preclinical models.
IBCN 2018: Association of Circulating Tumor -DNA Genomic Alterations with Outcomes in Metastatic Urothelial Carcinoma
Rotterdam, The Netherlands (UroToday.com) Petros Grivas studied if circulating Tumor -DNA genomic alterations (ctDNA GA) correlated with outcomes and signified therapy targets. Patients with urothelial carcinoma (UC) who underwent ctDNA analysis for potentially actionable GA via Guardant360 were identified. A 73-gene ctDNA next generation sequencing (NGS) panel from CLIA-licensed, CAP-accredited laboratory (Guardant Health, Inc.) offers complete exon sequencing in 19 cancer genes, critical exons in 54 genes, amplifications (18 genes), fusions (6 genes) & indels (23 genes) from 10 mL of peripheral blood.
IBCN 2018: A Non-Invasive Diagnostic Urine Assay to Safely Reduce the Need for Diagnostic Cystoscopy in Patients Presenting with Hematuria
Rotterdam, The Netherlands (UroToday.com) Kim E.M. van Kessel assessed the accuracy to detect bladder cancer of a previously developed molecular assay in a large prospective cohort of patients referred for hematuria. They prospectively included 1003 patients referred to the urology clinic for hematuria who received a cystoscopy. Mutation status of the FGFR3, TERT and HRAS genes and methylation of the OTX1, ONECUT2 and TWIST1 genes were determined. The predictive capacity of the urine assay, potential confounders and the association between potentially predictive variables and the detection of bladder cancer were determined via logistic regression analyses.